Home>Topics>Stocks>Exelixis

Exelixis EXEL

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. New Morningstar Analyst Report for Biogen Idec Inc

      Stock Reports

      Fri, 11 Apr 2014

      2010, after serving as CEO of development-stage biotech Exelixis for 14 years. While we see this as an unconventional choice ..... without commercial operations, we think his performance at Exelixis demonstrates a strong understanding of business development

    2. Is This the Year Exelixis Excels?

      Headlines

      Fri, 28 Mar 2014

      Exelixis EXEL announced this week that after a prespecified ..... value estimate and no-moat rating for Exelixis . While the stock had been trading around ..... later in 2014. Product Pipeline Is Full Exelixis is best known for its R&D prowess for

    3. Traders pound Exelixis

      Headlines

      Wed, 26 Mar 2014

      Shares of Exelixis ( EXEL -37.7% ) are down big on a 10x surge in volume in response the the DMC recommendation to continue the Comet-1 trial. Apparently

    4. Midday Gainers /Losers

      Headlines

      Wed, 26 Mar 2014

      ETAK +18% . KERX +18% . FFHL +17% . CXDC +14% . YONG +13% . EMAN +13% . SCS +12% . THTI +12% . Top 10 Losers: EXEL -36% . BODY -31% . REED -22% . PLUG -19% . BLDP -17% . FRAN -16% . GCA -16% . RLYP -15% . FCEL -14% . ARTX

    5. Overreaction to Exelixis' Lack of Early Success in Cancer Trial Provides Attractive Opportunity

      Commentary

      Wed, 26 Mar 2014

      Exelixis announced Tuesday that after a prespecified interim analysis for Cometriq ..... are maintaining our $7.50 fair value estimate and no-moat rating for Exelixis . While the stock was recently trading around our fair value estimate

    6. Premarket Gainers / Losers

      Headlines

      Wed, 26 Mar 2014

      Gainers: FIVE +18% . CXDC +16% . YONG +13% . YOKU +8% . HIMX +6% . OXGN +5% . Losers: EXEL -30% . BODY -20% . RGSE -12% . XGTI -11% . INSM -10% . ARTX -8% . IGT -7% . BLDP -7% . FRAN -7% . OIBR -7% . PLUG -6% . Post your comment!

    7. Exelixis trial for prostate-cancer drug given OK to continue

      Headlines

      Wed, 26 Mar 2014

      Monitoring Committee supervising Exelixis ' ( EXEL ) Phase III trial of its Cabozantinib ..... following an interim analysis. Exelixis ' PR doesn't mention a futility ..... castration-resistant prostate cancer. Exelixis continues to expect that it will

    8. 4 Reasons To Be Bullish On Exelixis In The Near Term

      Headlines

      Tue, 25 Mar 2014

      Vimer Moving on a fast track, Exelixis ( EXEL ) is a bio-pharmaceutical company ..... prostate, renal and liver cancer. Exelixis has impressive clinical achievements ..... future development. In 2014, Exelixis expects to achieve multiple clinical

    9. Europe approves COMETRIQ

      Headlines

      Tue, 25 Mar 2014

      The European Commission gives Exelixis ' ( EXEL ) COMETRIQ (cabozantinib) its OK for the treatment of medullary thyroid carcinoma . The Committee on Orphan Medicinal Products

    10. Cramer's Lightning Round - I Don't Know What Annaly Is Up To (3/13/14)

      Headlines

      Fri, 14 Mar 2014

      Coupons.com ( COUP ): "It came public in a tough time for IPOs, but it is a good stock. Buy, buy, buy." Exelixis ( EXEL ): "We looked at this and we liked it, but it is a speculative stock." Time Warner ( TWX ): "TWX is the stock

    « Prev12345Next »
    Content Partners